EP0705433A4 - Compositions and methods for anti-addictive narcotic analgesis acivity screening and treatments - Google Patents
Compositions and methods for anti-addictive narcotic analgesis acivity screening and treatmentsInfo
- Publication number
- EP0705433A4 EP0705433A4 EP94920259A EP94920259A EP0705433A4 EP 0705433 A4 EP0705433 A4 EP 0705433A4 EP 94920259 A EP94920259 A EP 94920259A EP 94920259 A EP94920259 A EP 94920259A EP 0705433 A4 EP0705433 A4 EP 0705433A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- analgesis
- acivity
- treatments
- screening
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000003533 narcotic effect Effects 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9486—Analgesics, e.g. opiates, aspirine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81612 | 1979-10-03 | ||
US8161293A | 1993-06-23 | 1993-06-23 | |
US26150094A | 1994-06-16 | 1994-06-16 | |
US261500 | 1994-06-16 | ||
PCT/US1994/006883 WO1995000848A1 (en) | 1993-06-23 | 1994-06-17 | Compositions and methods for anti-addictive narcotic analgesis acivity screening and treatments |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0705433A1 EP0705433A1 (en) | 1996-04-10 |
EP0705433A4 true EP0705433A4 (en) | 2001-09-26 |
Family
ID=26765751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP94920259A Withdrawn EP0705433A4 (en) | 1993-06-23 | 1994-06-17 | Compositions and methods for anti-addictive narcotic analgesis acivity screening and treatments |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0705433A4 (en) |
JP (1) | JPH08512129A (en) |
AU (1) | AU7112094A (en) |
CA (1) | CA2164966A1 (en) |
WO (1) | WO1995000848A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5882944A (en) * | 1993-06-23 | 1999-03-16 | The Regents Of The University Of California | Methods for G protein coupled receptor activity screening |
EP0869975B1 (en) * | 1995-12-11 | 2007-08-15 | New England Medical Center Hospitals, Inc. | Assay for and uses of peptide hormone receptor ligands |
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
GB9815618D0 (en) * | 1998-07-18 | 1998-09-16 | Univ Manchester | Treatment of dyskinesia |
CN1420929A (en) | 2000-04-07 | 2003-05-28 | 阿瑞那制药公司 | Non-endogenous, constitutively activated known G protein-coupled receptors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5061715A (en) * | 1989-11-13 | 1991-10-29 | Merrell Dow Pharmaceuticals Inc. | Prevention of glycoprotein enveloped virus infectivity by quinolyl- and isoquinolyloxazole-2-zones |
-
1994
- 1994-06-17 CA CA002164966A patent/CA2164966A1/en not_active Abandoned
- 1994-06-17 WO PCT/US1994/006883 patent/WO1995000848A1/en not_active Application Discontinuation
- 1994-06-17 JP JP7502986A patent/JPH08512129A/en active Pending
- 1994-06-17 AU AU71120/94A patent/AU7112094A/en not_active Abandoned
- 1994-06-17 EP EP94920259A patent/EP0705433A4/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
COSTA E.M. ET AL: "Opioid agonists binding and responses in SH-SY5Y cells", LIFE SCIENCES, vol. 50, 1991, pages 73 - 81, XP001008484 * |
Also Published As
Publication number | Publication date |
---|---|
WO1995000848A1 (en) | 1995-01-05 |
CA2164966A1 (en) | 1995-01-05 |
JPH08512129A (en) | 1996-12-17 |
AU7112094A (en) | 1995-01-17 |
EP0705433A1 (en) | 1996-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2294465A8 (en) | Perfluoroelastomeric compositions and methods | |
ZA963844B (en) | Seed treatment composition and method | |
EP0876145A4 (en) | Taxane composition and method | |
ZA964733B (en) | Ob protein compositions and methods | |
AU5439996A (en) | Compositions and methods for treating pain | |
AU7564694A (en) | Erection-inducing methods and compositions | |
EP0851759A4 (en) | Compounds and methods | |
PL321935A1 (en) | Electroplating compositions and methods | |
GB2298713B (en) | Method and composition | |
EP0734398A4 (en) | Compounds and methods | |
ZA95701B (en) | Rivets-nails and methods for their implementation | |
EP0705433A4 (en) | Compositions and methods for anti-addictive narcotic analgesis acivity screening and treatments | |
AU6368394A (en) | Polymer-polypeptide composition and method | |
ZA948585B (en) | Cleaning methods and compositions for produce | |
GB2318356B (en) | Composition and method | |
GB9526675D0 (en) | Bituminous composition and process | |
AU8079094A (en) | Anti-paramyxovirus screening method and vaccine | |
GB9420539D0 (en) | Process and composition | |
GB9508546D0 (en) | Method and composition | |
EP0799225A4 (en) | Compounds and methods | |
GB9414888D0 (en) | Method and composition | |
GB9419087D0 (en) | Method and composition | |
GB9308051D0 (en) | Method and composition | |
GB9503463D0 (en) | "Cleaning composition and method" | |
GB9301720D0 (en) | Method and compositions for treating anoestrus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960113 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RHK1 | Main classification (correction) |
Ipc: G01N 33/554 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20010810 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 38/00 A, 7G 01N 33/50 B, 7G 01N 33/94 B, 7C 07K 14/705 B, 7A 61K 31/47 B |
|
17Q | First examination report despatched |
Effective date: 20020131 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20020611 |